ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia